TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Uptake of Medical Male Circumcision Among Men With Sexually Transmitted Infections

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male~* 18 years or older~* Seeking STI care at the Bwaila STI clinic~* Not circumcised~* Healthcare workers at Bwaila STI and VMMC clinic~Exclusion Criteria:~* \< 18 years of age

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: t

Study Arms:
- Standard of care (Type: PLACEBO_COMPARATOR): Participants in this arm will be offered Standard of Care (SOC) referral process for voluntary medical male circumcision (VMMC) services
- Block 1 (intensified health education) (Type: EXPERIMENTAL): Participants in this arm will be offered intensified health education
- Block 2 (intensified health education and SMS/telephonic tracing) (Type: EXPERIMENTAL): Participants in this arm will be offered intensified health education and SMS/telephonic tracing
- Block 3 (intensified health education, SMS/telephonic tracing and transport reimbursement) (Type: EXPERIMENTAL): Participants in this arm will be offered intensified health education, SMS/telephonic tracing and transport reimbursement

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female diagnosed with type 2 diabetes~* Age at least 50 years at screening and presence of cardiovascular disease, or age at least 60 years at screening and presence of at least one cardiovascular risk factor~Exclusion Criteria:~* Current or previous (within 90 days prior to screening) treatment with any GLP-1 (glucagon-like peptide-1) receptor agonist, DPP-4 (dipeptidyl peptidase-4) inhibitor or pramlintide~* Family or personal history of multiple endocrine neoplasia type 2 (MEN 2) or medullary thyroid carcinoma (MTC)~* History of pancreatitis (acute or chronic)~* History of major surgical procedures involving the stomach potentially affecting absorption of trial product (e.g. subtotal and total gastrectomy, sleeve gastrectomy, gastric bypass surgery)~* Subjects presently classified as being in New York Heart Association (NYHA) Class IV heart failure~* Planned coronary, carotid or peripheral artery revascularisation known on the day of screening~* Any of the following: myocardial infarction, stroke or hospitalisation for unstable angina or transient ischaemic attack within the past 60 days prior to screening~* Chronic or intermittent hemodialysis or peritoneal dialysis or severe renal impairment (corresponding to eGFR (glomerular filtration rate, estimated) below 30 mL/min/1.73 m\^2)~* History or presence of malignant neoplasms within the last 5 years (except basal and squamous cell skin cancer and carcinoma in situ)

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Oral semaglutide (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Subjects will be eligible for inclusion in the study if all of the following criteria are met:~1. Low risk prostate cancer diagnosed using one transrectal ultrasound guided biopsy (TRUS)using from 10 to 24 cores performed less than 12 months prior to enrolment, and showing the following:~   * Gleason 3 + 3 prostate adenocarcinoma as a maximum,~  * Two (2) to three (3) cores positive for cancer~  * A maximum cancer core length of 5 mm in any core.~2. Cancer clinical stage up to T2a (pathological or radiological up to T2c disease permitted)~3. Serum prostate specific antigen (PSA) of 10 ng/mL or less~4. Prostate volume equal or greater than 25 cc and less than 70 cc.~5. Male subjects aged 18 years or older.~Exclusion Criteria:~Subjects will not be eligible for the study if meeting any of the following criteria:~1. Unwillingness to accept randomisation to either of the two arms of the study~2. Any prior or current treatment for prostate cancer, including surgery, radiation therapy (external or brachytherapy) or chemotherapy.~3. Any surgical intervention for benign prostatic hypertrophy~4. Life expectancy less than 10 years.~5. Any condition or history of illness or surgery that may pose an additional risk to men undergoing the VTP procedure.~6. Participation in another clinical study or recipient of an investigational product within 1 month of study entry.~7. Subject unable to understand the patient's information document, to give consent or complete the study tasks.~8. Subject in custody and or in residence in a nursing home or rehabilitation facility~9. Contra-indication to Magnetic resonance Imaging (MRI) (e.g., pacemaker, history of allergic reaction to gadolinium), or factors excluding accurate reading of pelvic MRI (e.g., hip prosthesis)~10. Any condition or history of illness or surgery that may pose an additional risk to men undergoing the TOOKAD® Soluble VTP procedure.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TOOKAD® Soluble (Type: EXPERIMENTAL): TOOKAD® Soluble, lyophilized formulation, given at a dose of 4mg/Kg.
- Active Surveillance (Type: NO_INTERVENTION): Active surveillance is one of the management strategy in men who have low-risk prostate cancer

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Continuation Trial for Subjects With Systemic Lupus Erythematosus That Have Completed Protocol LBSL02

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Primary Inclusion Criteria~1. Have completed the LBSL02 trial and achieved a satisfactory response.~Primary Exclusion Criteria~1. Required more than 2 courses of corticosteroids for treatment of severe SLE flares in the last 5 months of LBSL02.~2. Had an SLE flare during the last 30 days of LBSL02 and through the 1st dose in LBSL99.~3. Used any of the following prohibited medications during their participation in LBSL02:~   * Other investigational agents.~  * Biologic therapeutic agents: adalimumab (Humira™), etanercept (Enbrel™), infliximab (Remicade™), and rituximab (Rituxan™).~  * Intravenous cyclophosphamide.~  * Corticosteroids \>100 mg/day prednisone equivalent for reasons other than severe SLE flare.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Belimumab 10 mg/kg (Type: EXPERIMENTAL): Belimumab 10 mg/kg IV over one hour every 28 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Transseptal Needle Versus Radiofrequency Energy for Left Atrial Access

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing radiofrequency ablation within the left atrium through a transseptal approach~* Patients greater than 18 years of age~Exclusion Criteria:~* Patients unable to grant informed, written consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Radiofrequency energy needle (Type: EXPERIMENTAL): Radiofrequency energy needle for transseptal access
- Mechanical needle (Type: ACTIVE_COMPARATOR): Mechanical (Brockenbrough) needle for transseptal access

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Optimal Treatment for Women With a Persisting Pregnancy of Unknown Location

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Female with a persisting pregnancy of unknown location:~* A pregnancy of unknown location is defined as a pregnancy in a woman with a positive pregnancy test but no definitive signs of pregnancy in the uterus or adnexa on ultrasound imaging. A definitive sign of gestation includes ultrasound visualization of a gestational sac with a yolk sac (with or without an embryo) in the uterus or in the adnexa. Ultrasound must be performed within 7 days prior to randomization.~* Persistence of hCG is defined as at least 2 serial hCG values (over 2-14 days), showing \< 15% rise per day, or \< 50% fall between the first and last value.~* Patient is hemodynamically stable, hemoglobin \>10 mg/dL~* Greater than or 18 years of age~Exclusion Criteria:~* Hemodynamically unstable in need of acute treatment~* Most recent hCG \> 5000 mIU/mL~* Patient obtaining care in relation to a recently completed pregnancy (delivery, spontaneous or elective abortion)~* Diagnosis of gestational trophoblastic disease~* Subject unwilling or unable to comply with study procedures~* Known hypersensitivity to MTX~* Presence of clinical contraindications for treatment with MTX~* Prior medical or surgical management of this gestation~* Subject unwilling to accept a blood transfusion

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Expectant Management (Type: ACTIVE_COMPARATOR): Subjects will have their PPUL expectantly managed using serum hCG monitoring.
- Uterine evacuation with MTX for some (Type: ACTIVE_COMPARATOR): Subjects will undergo a uterine evacuation. If hCG levels do not sufficiently decrease after the uterine evacuation, the subject will be treated with methotrexate. If hCG levels do sufficiently decrease after the uterine evacuation, no further treatment is required.
- Empiric treatment with MTX for all (Type: ACTIVE_COMPARATOR): Subjects will be treated with methotrexate, receiving one dose on day 0 and a subsequent dose on day 4. Additional doses will be administered as needed based on hCG levels.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent, and child assent as age-appropriate, obtained before any trial-related activities (Trial-related activities are any procedure that would not have been performed during normal management of the subject). The parents or legal representative of the child must sign and date the Informed Consent Form according to local requirements. The child, if possible, parents or legal representative of the child must sign and date the Child Assent Form according to local requirements~* Male or female diagnosed with type 1 diabetes mellitus (T1DM) (based on clinical judgement and supported by laboratory analysis as per local guidelines)~* Ongoing daily treatment with insulin (any regimen) for at least 3 months prior to Visit 1 (screening). No OADs (oral anti-diabetic drugs) are allowed~* HbA1c (glycosylated haemoglobin) maximum 11%~Exclusion Criteria:~* Known or suspected hypersensitivity to trial product(s) or related products~* Previous participation in this trial. Participation is defined as randomisation~* Girls who are pregnant, breastfeeding or intend to become pregnant~* Girls who have had menarche and are not using adequate contraceptive measures according to local requirements~* Known hypoglycaemic unawareness or recurrent severe hypoglycaemic events as judged by the Investigator (trial physician)~* More than 1 diabetic ketoacidosis requiring hospitalisation within the last 3 months prior to Visit 1~* Significant concomitant disease, except for conditions associated with type 1 diabetes mellitus, which in the Investigator's opinion could interfere with the trial~* The receipt of any investigational drug within 1 month prior to Visit 1

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Insulin Degludec + Insulin Aspart (Type: EXPERIMENTAL): None
- Insulin Detemir +Insulin Aspart (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Behavioral Activation (BA) for Medication-responsive Chronically Depressed Patients With Impaired Social Functioning

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* adults aged 20-75 years~* a primary diagnosis of Dysthymic Disorder, Chronic major depressive disorder or double depression~* a \>50% decrease in 17 item Hamilton Rating Scale for Depression (HRSD-17) score and a final HRSD-17 score ≤ 10 with an adequate antidepressant medication (ADM) trial (\> 4 weeks on at least 50% Physician's Desk Reference maximum ADM dose)~* a rating of 1 (very much improved) or 2 (much improved) on the Clinical Global Impressions-Improvement scale (CGI-I)~* continued functional impairment, defined by scores \>1.9 on the Social Adjustment Scale (SAS)~* unemployment (jobless, looking for work) according to the Bureau of Labor Statistics: jobless and looking and available for work, or underemployed.~Exclusion Criteria:~* Structured Clinical Interview for Diagnostic and Statistical Manual, fourth edition (DSM-IV) Axis I disorders-diagnosed cognitive or psychotic disorders~* bipolar disorder~* active eating disorders~* severe borderline personality disorder~* alcohol or drug dependence (except nicotine) in the last 6 months~* current suicide risk~* unstable medical conditions~* use of psychotropic medications other than antidepressants

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Behavioral Activation for Return to Work (Type: EXPERIMENTAL): BA is a manualized psychotherapy with comparable efficacy to cognitive behavioral treatment and antidepressant medication for acute treatment of depression. In this study, BA's focus was shifted to target work dysfunction by activating the patient into employment-related goals. BA-W consisted of 12 50-minute weekly sessions. Conceptualizing work dysfunction as a product of avoidance patterns and low levels of positive reinforcement, the treatment addressed maladaptive coping strategies such as avoidance as maintaining work dysfunction beyond remission of symptoms. Rather than broadly activating patients, activity scheduling focused on tasks such as sending out resumes, calling for job interviews, and networking to meet potential employers.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: rTSST-1 Variant Vaccine Phase 1 First-in-man Trail

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* male and female~* 18 - 64 years~* written informed consent~* physical exam: no abnormal findings unless considered irrelevant by the investigator~* uneventful medical history~* females: adequate contraception~Exclusion Criteria:~* pregnancy~* positive virology markers~* signs and symptoms of relevant autoimmunity~* TSST-1 Ab titer \> 1:2000

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- Dose Group 1 (Type: EXPERIMENTAL): Treatment: rTSST-1 Variant Candidate Vaccine 100 ng
- Dose Group 2 (Type: EXPERIMENTAL): Treatment: rTSST-1 Variant Candidate Vaccine 300 ng
- Dose Group 3 (Type: EXPERIMENTAL): Treatment: rTSST-1 Variant Candidate Vaccine 1 µg
- Dose Group 4 (Type: EXPERIMENTAL): Treatment: rTSST-1 Variant Candidate Vaccine 3 µg
- Dose Group 5 (Type: EXPERIMENTAL): Treatment: rTSST-1 Variant Candidate Vaccine 10 µg
- Dose Group 6 (Type: EXPERIMENTAL): Treatment: rTSST-1 Variant Candidate Vaccine 30 µg
- Dose Group 0 (Type: PLACEBO_COMPARATOR): Control: Al(OH)3 Adjuvant

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria: - For Japan only: Male or female, age above or equal to 20 years at the time of signing inform consent - Subjects diagnosed with type 2 diabetes and treated with diet and exercise for at least 30 days before screening - HbA1c 7.0 - 10.0 % (53 - 86 mmol/mol) (both inclusive) Exclusion Criteria: - Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using adequate contraceptive method (adequate contraceptive measures as required by local regulation or practice) throughout the trial including the 5 week follow-up period. United Kingdom: Adequate contraceptive measures are defined as established use of oral, injected or implanted hormonal methods of contraception, placement of an intrauterine device or intrauterine system, barrier methods of contraception (condom or occlusive cap with spermicidal foam/gel/film/cream/suppository), male sterilisation (where partner is sole partner of subject), or true abstinence (when in line with preferred and usual lifestyle) - Any chronic disorder or severe disease which, in the opinion of the investigator, might jeopardise subject's safety or compliance with the protocol - Treatment with any glucose lowering agent(s) in a period of 90 days prior to screening. An exception is short-term treatment (no longer than 7 days in total) with insulin in connection with inter-current illness - History of chronic or idiopathic acute pancreatitis - Screening calcitonin value above or equal to 50 ng/L (pg/mL) - Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2) - Impaired renal function defined as eGFR (estimated glomerular filtration rate ) below 30 mL/min/1.73 m\^2 per modification of diet in renal disease (MDRD) formula (4 variable version) - Acute coronary or cerebrovascular event within 90 days before randomisation - Heart failure, New York Heart Association class IV

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Semaglutide 1.0 mg (Type: EXPERIMENTAL): None
- Semaglutide 0.5 mg (Type: EXPERIMENTAL): None
- Semaglutide placebo 1.0 mg (Type: PLACEBO_COMPARATOR): None
- Semaglutide placebo 0.5 mg (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Promoting Gastrointestinal Health and Reducing Subclinical Inflammation in Obese Individuals

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Obese or overweight men or women (body mass index, BMI, ≥25 kg/m2)~* Free of known gastrointestinal disease~* No supplements use (excluding multivitamin)~* Participate in less than 1 h of exercise per week~* Have not taken antibiotics in the last six months~Exclusion Criteria:~* Men and women with fruits and vegetable intake exceeding 2 servings/day~* Men and women with whole grain intakes exceeding 1 serving/day~* Pregnant~* Do not fit the inclusion criteria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Control (Type: EXPERIMENTAL): 3 servings of refined grains per day.
- Fruits and Vegetables (Type: EXPERIMENTAL): 5 servings of fruits and vegetable per day.
- Whole Grain (Type: EXPERIMENTAL): 3 servings of whole grains per day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete